Effect of biologic treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: A Real-World Data study

Since 2022, mepolizumab and omalizumab are reimbursed for severe chronic rhinosinusitis with nasal polyps (CRSwNP) in Belgium. Their efficacy has been demonstrated in large double-blind placebo-controlled trials. However, only very limited reports on real-world efficacy data have been published.

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: An-sofie Viskens, Laura Bollen, Elien Borgers, Florence Rogister, Stijn Halewyck, Valerie Hox, Mark Jorissen, Winde Lemmens, Kato Speleman, Laura Van Gerven, Olivier Vanderveken, Benedicte Verhaeghe, Peter Hellings Source Type: research